BOLT Bolt Biotherapeutics
- 0.750
- +0.002+0.32%
- 0.731
- -0.019-2.49%
Bolt Biotherapeutics News
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bolt Biotherapeutics (BOLT), Laboratory (LH) and Biophytis (OtherBPTSY)
Bolt Biotherapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Daré Bioscience (DARE) and Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics: Hold Rating Amid Clinical Setbacks and High-Risk Innovations
Bolt Biotherapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics' BDC-1001: A Promising Future in Oncology Drives Buy Rating
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), Pliant Therapeutics (PLRX) and Bolt Biotherapeutics (BOLT)
Analysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)
Promising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt Biotherapeutics
Analysts Offer Insights on Healthcare Companies: Biora Therapeutics (BIOR), Bolt Biotherapeutics (BOLT) and Immunovant (IMVT)
Bolt Biotherapeutics: Buy Rating Justified by Promising Clinical Results and Strong Financial Outlook
FDA Orphan Drug Approval and Promising Sales Forecast Boost Bolt Biotherapeutics' Buy Rating
JonesTrading Sticks to Their Buy Rating for Bolt Biotherapeutics (BOLT)
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price Target
Bolt Biotherapeutics Analyst Ratings
Bolt Biotherapeutics Analyst Ratings
H.C. Wainwright Remains a Buy on Bolt Biotherapeutics (BOLT)
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price Target
H.C. Wainwright Sticks to Their Buy Rating for Bolt Biotherapeutics (BOLT)
Analysis
Price Target
No Data
